Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics
Leonard J. Appleman(University of Pittsburgh), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Thomas Grader‐Beck(Johns Hopkins University), André A. F. L. van Puijenbroek(Harvard University), Dimitrios Tzachanis(Dana-Farber Cancer Institute)
Cited by 49
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859